Opiant Pharmaceuticals Inc – Underwriting Agreements Watch

from S-3 44 pages Opiant Pharmaceuticals, Inc. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement

from SC 13G/A ~1 page Exhibit 1 Joint Acquisition Statement Pursuant to Section 240.13d-1

from 8-K 39 pages Open Market Sale Agreementsm

from SC 13D/A 3 pages October 4, 2018 Opiant Pharmaceuticals, Inc. Attn: Dr. Roger Crystal, Chief Executive Officer 201 Santa Monica Boulevard, Suite 500 Santa Monica, Ca 90401 Re: Beneficial Ownership Limitation Dear Dr. Crystal: Reference Is Made to the Separation Agreement and General Release (The “Agreement”), Dated as of September 5, 2017, Between Opiant Pharmaceuticals, Inc. (The “Company”) and Myself. Capitalized Terms Not Defined in This Letter Shall Have the Meanings Ascribed to Them in the Agreement. the Company and I Hereby Agree as Follows

from 8-K 40 pages Opiant Pharmaceuticals, Inc. 705,882 Shares of Common Stock (Par Value $0.001 Per Share) Underwriting Agreement